Susan Haigney

1 week ago | biopharminternational.com | Susan Haigney

The biopharma industry is seeing growth in innovation with new treatments for cancer and autoimmune diseases and the development of specialized medicines. New technologies, such as artificial intelligence and machine learning, are also having an impact on drug development and manufacturing. New drugs come with the cost to develop and produce before they can reach patients.

3 weeks ago | biopharminternational.com | Susan Haigney

Integra Therapeutics, a creator of gene-writing tools, announced it is presenting new pre-clinical data at the 28th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is taking place in New Orleans May 13–17. According to the company, its technology has been used to create chimeric antigen receptor (CAR) T cells that allow for the expression of complex CARs, such as bispecific and with a kill switch, in a single DNA donor.

3 weeks ago | biopharminternational.com | Susan Haigney

Oncology treatments are advancing quickly and encompass a range of promising areas, such as immune checkpoint inhibitors, antibody drug conjugates, T cell engagers, and in vivo chimeric antigen receptor (CAR) T-cell therapy, according to Ryan Larson, PhD, SVP, head of Research at Umoja BioPharma.

1 month ago | biopharminternational.com | Susan Haigney

FDA Director Martin Makary announced on May 6, 2025 that he has appointed Dr. Vinay Prasad, MD, MPH as the director of FDA’s Center for Biologics Evaluation and Research. Prasad is a hematologist-oncologist and was previously a professor in the department of Epidemiology and Biostatistics at the University of California San Francisco (UCSF).

1 month ago | biopharminternational.com | Susan Haigney

Adeno-associated virus (AAV) vectors are commonly used for gene therapies, according to Noah Kopcho, field application scientist at Gyros Protein Technologies. AAV vectors come with challenges in productions, however. “Namely, compared to other vectors, AAV often has lower titers,” says Kopcho. “This can present problems with scalability. During the production and purification workflow, there are several different contaminants that need to be kept in mind, and purity is often essential.